drugset
drugset / Trial / NCT04283513

Treatment of Hemorrhagic Fever With Ribavirin

NCT04283513 ↗

Phase 2 Suspended 50 enrolled U.S. Army Medical Research and Development Command
NaSingle-groupOpen-labelTreatment

Summary

Multisite protocol to provide IV Ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS)

Timeline

Start
2022-10-31
Primary completion
2027-04
Completion
2027-07

Outcome

Outcome not reported

Stopped: “Product expired, new lots not available”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 16 mg/kg Intravenous

Indications

hemorrhagic fever